Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Scientific Reports|July 2, 2025
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancersShogo Adomi, Kazuko Sakai, Yurie Kura, et al.
Arerugi = [Allergy]|October 15, 2015
PHYSIOLOGIC AIRWAY RESPONSES TO INHALED HISTAMINE AND ACETYLCHOLINE IN PATIENTS WITH MILD ASTHMA AS ANALYZED BY FORCED OSCILLATIONNaomi Tsurikisawa, Chiyako Oshikata, Takahiro Tsuburai, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 19, 2023
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational studyWataru Fukuokaya, Yuhei Koike, Yuji Yata, et al.
Urologic Oncology|December 28, 2025
Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancerTsuyoshi Morita, Yutaka Yamamoto, Saizo Fujimoto, et al.
Translational Andrology and Urology|August 25, 2021
Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patientsMamoru Hashimoto, Kazutoshi Fujita, Takahito Nakayama, et al.
Arerugi = [Allergy]|December 11, 2014
[Comparison of exhaled nitric oxide levels measured by two offline methods and the NO breath® method in Japan]Jun Ito, Takahiro Tsuburai, Ryo Atsuta, et al.
Anti-Cancer Drugs|September 6, 2021
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinomaMamoru Hashimoto, Takahito Nakayama, Saizo Fujimoto, et al.
The Prostate|January 16, 2025
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate CancerTakashi Ueda, Keita Hayakawa, Go Horiguchi, et al.
Anticancer Research|August 1, 2025
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With ImmunotherapyKoichi Sugimoto, Takafumi Minami, Shingo Toyoda, et al.
International Journal of Clinical Oncology|July 13, 2022
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective studyTaigo Kato, Kazutoshi Fujita, Takafumi Minami, et al.
Pageof 9